See more : Tamilnadu Telecommunications Limited (TNTELE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Avid Bioservices, Inc. (CDMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avid Bioservices, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- enGene Holdings Inc. Common Stock (ENGN) Income Statement Analysis – Financial Results
- Thai Nam Plastic Public Company Limited (TNPC.BK) Income Statement Analysis – Financial Results
- Strauss Group Ltd. (SGLJF) Income Statement Analysis – Financial Results
- iCollege Limited (ICT.AX) Income Statement Analysis – Financial Results
- Mobilus Corporation (4370.T) Income Statement Analysis – Financial Results
Avid Bioservices, Inc. (CDMO)
About Avid Bioservices, Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.91M | 149.27M | 119.60M | 95.87M | 59.70M | 53.60M | 53.62M | 57.63M | 44.69M | 26.78M | 22.40M | 21.68M | 15.23M | 13.49M | 27.94M | 18.15M | 6.09M | 3.71M | 3.19M | 4.96M | 3.31M | 3.92M | 3.77M | 979.00K | 1.00K | 100.00K | 500.00K | 300.00K | 3.10M | 100.00K |
| Cost of Revenue | 132.59M | 117.79M | 82.95M | 66.56M | 55.77M | 46.38M | 56.55M | 38.26M | 22.97M | 15.59M | 13.11M | 12.60M | 10.15M | 7.30M | 8.72M | 9.06M | 4.80M | 3.30M | 3.30M | 4.40M | 2.21M | 2.86M | 0.00 | -412.00K | -516.00K | 3.50M | -700.00K | -300.00K | 0.00 | 1.00M |
| Gross Profit | 7.32M | 31.48M | 36.65M | 29.31M | 3.93M | 7.22M | -2.92M | 19.37M | 21.72M | 11.19M | 9.29M | 9.09M | 5.08M | 6.20M | 19.23M | 9.09M | 1.29M | 412.00K | -104.00K | 558.00K | 1.10M | 1.06M | 3.77M | 1.39M | 517.00K | -3.40M | 1.20M | 600.00K | 3.10M | -900.00K |
| Gross Profit Ratio | 5.23% | 21.09% | 30.64% | 30.57% | 6.59% | 13.48% | -5.45% | 33.61% | 48.61% | 41.78% | 41.48% | 41.91% | 33.35% | 45.92% | 68.81% | 50.06% | 21.16% | 11.11% | -3.26% | 11.25% | 33.25% | 27.06% | 100.00% | 142.08% | 51,700.00% | -3,400.00% | 240.00% | 200.00% | 100.00% | -900.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.30M | 59.53M | 43.00M | 27.72M | 24.31M | 35.69M | 29.46M | 24.66M | 18.42M | 18.28M | 15.88M | 12.42M | 11.16M | 9.67M | 8.74M | 13.51M | 7.38M | 8.08M | 8.80M | 7.60M | 30.00M | 1.70M | 0.00 |
| General & Administrative | 25.20M | 27.18M | 20.63M | 16.76M | 14.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Selling & Marketing | 800.00K | 700.00K | 600.00K | 300.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 19.33M | 18.55M | 18.69M | 17.27M | 13.13M | 11.46M | 11.42M | 8.18M | 6.98M | 7.15M | 6.45M | 6.56M | 5.10M | 4.23M | 2.99M | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Other Expenses | 1.00 | 1.00M | -81.00K | 133.00K | 355.00K | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| Operating Expenses | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 47.63M | 78.08M | 61.69M | 45.00M | 37.44M | 47.15M | 40.88M | 32.84M | 25.40M | 25.43M | 22.32M | 18.98M | 16.26M | 13.90M | 11.73M | 15.98M | 11.60M | 12.83M | 16.00M | 12.80M | 33.60M | 2.80M | 900.00K |
| Cost & Expenses | 158.59M | 145.67M | 104.18M | 83.63M | 70.29M | 59.23M | 73.00M | 85.89M | 101.05M | 77.28M | 58.11M | 50.04M | 57.30M | 48.18M | 41.56M | 34.47M | 30.23M | 25.62M | 22.28M | 20.66M | 16.11M | 14.59M | 15.98M | 11.19M | 12.31M | 19.50M | 12.10M | 33.30M | 2.80M | 1.90M |
| Interest Income | 0.00 | 2.60M | 2.68M | 133.00K | 474.00K | 282.00K | 102.00K | 108.00K | 722.00K | 142.00K | 349.00K | 322.00K | 41.00K | 1.05M | 116.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.34M | 2.60M | 2.68M | 1.16M | 8.00K | 11.00K | 27.00K | 7.00K | 14.00K | 1.00K | 5.00K | 54.00K | 90.00K | 516.00K | 997.00K | 408.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.11M | 7.21M | 4.48M | 3.45M | 3.09M | 2.75M | 2.56M | 2.46M | 1.54M | 1.04M | 986.00K | 1.09M | 908.00K | 652.00K | 1.12M | 503.00K | 486.00K | 866.00K | 415.00K | 325.00K | 2.19M | 1.38M | 424.00K | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| EBITDA | -11.48M | 10.91M | 19.90M | 15.70M | -7.38M | -2.59M | -16.82M | 3.76M | 5.02M | -49.32M | -34.37M | -28.64M | -41.12M | -32.98M | -13.05M | -15.61M | -23.65M | -21.04M | -18.67M | -15.38M | -10.61M | -9.29M | -11.79M | -9.80M | -11.79M | -18.50M | -11.30M | -32.90M | 500.00K | -1.60M |
| EBITDA Ratio | -8.21% | 3.08% | 12.83% | 12.91% | -17.14% | -10.49% | -35.95% | -48.85% | -121.07% | -184.15% | -153.44% | -129.27% | -276.18% | -257.09% | -44.72% | -87.12% | -388.22% | -567.53% | -623.14% | -310.12% | -320.19% | -236.90% | -313.17% | -1,000.20% | -960,400.00% | -18,800.00% | -2,180.00% | -10,900.00% | 22.58% | 3,400.00% |
| Operating Income | -18.68M | -2.61M | 10.86M | 8.92M | -10.59M | -5.62M | -20.64M | -28.26M | -56.36M | -50.50M | -35.71M | -28.35M | -42.07M | -34.69M | -13.61M | -16.32M | -24.14M | -21.91M | -19.08M | -15.70M | -12.80M | -10.67M | -12.22M | -10.21M | -12.31M | -19.40M | -11.60M | -33.00M | 300.00K | -1.80M |
| Operating Income Ratio | -13.35% | -1.75% | 9.08% | 9.31% | -17.73% | -10.49% | -38.49% | -49.04% | -126.12% | -188.56% | -159.39% | -130.76% | -276.18% | -257.09% | -48.72% | -89.89% | -396.19% | -590.88% | -597.65% | -316.68% | -386.12% | -272.12% | -324.43% | -1,043.21% | -1,231,000.00% | -19,400.00% | -2,320.00% | -11,000.00% | 9.68% | -1,800.00% |
| Total Other Income/Expenses | -8.25M | -2.01M | -2.76M | -1.03M | 119.00K | 282.00K | 75.00K | 101.00K | 708.00K | 141.00K | 344.00K | -1.43M | -49.00K | 536.00K | 13.61M | 16.32M | 964.00K | 1.11M | 2.02M | 252.00K | -1.55M | 0.00 | 0.00 | -9.00K | -2.19M | 499.00K | 0.00 | 0.00 | -200.00K | -5.00M |
| Income Before Tax | -26.93M | 2.00M | 12.66M | 11.21M | -10.47M | -5.34M | -20.56M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -34,151.00B | -34,151.00B | -14,494.00B | -16,524.00B | 0.00 | 0.00 | -17.85M | 0.00 | -14.35M | 0.00 | 0.00 | -10.22M | -14.50M | -19.00M | 0.00 | 0.00 | 100.00K | -6.80M |
| Income Before Tax Ratio | -19.25% | 1.34% | 10.59% | 11.70% | -17.53% | -9.96% | -38.35% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -224,190,901.33% | -253,120,367.63% | -51,869,877.97% | -91,036,306.54% | 0.00% | 0.00% | -559.16% | 0.00% | -432.86% | 0.00% | 0.00% | -1,044.13% | -1,450,000.00% | -19,000.00% | 0.00% | 0.00% | 3.23% | -6,800.00% |
| Income Tax Expense | 113.83M | 1.44M | -115.01M | -2.29M | -3.21M | -284.00K | -1.29M | -2.36M | 722.00K | 142.00K | 349.00K | -1.03M | 536.00B | 536.00B | -881.00B | -208.00B | -964.00K | -1.11M | -2.02M | -252.00K | 0.00 | 889.00K | -500.00K | -678.00K | 2.20M | 100.00K | 200.00K | 200.00K | 0.00 | 5.10M |
| Net Income | -140.75M | 560.00K | 127.67M | 11.21M | -7.26M | -4.22M | -21.81M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -42.12M | -34.15M | -14.49M | -16.52M | -23.18M | -20.80M | -17.06M | -15.45M | -14.35M | -11.56M | -11.72M | -9.54M | -14.51M | -19.50M | -11.80M | -33.20M | 300.00K | -6.90M |
| Net Income Ratio | -100.60% | 0.38% | 106.75% | 11.70% | -12.15% | -7.86% | -40.68% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -276.50% | -253.12% | -51.87% | -91.04% | -380.37% | -560.84% | -534.33% | -311.60% | -432.86% | -294.80% | -311.15% | -973.95% | -1,451,400.00% | -19,500.00% | -2,360.00% | -11,066.67% | 9.68% | -6,900.00% |
| EPS | -2.23 | 0.01 | 2.08 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| EPS Diluted | -2.23 | 0.01 | 1.81 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| Weighted Avg Shares Out | 63.20M | 62.27M | 61.48M | 58.22M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
| Weighted Avg Shares Out (Dil) | 63.20M | 63.78M | 70.47M | 59.43M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2022 Results - Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2022 Earnings Conference Call June 29, 2022 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak -...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022
TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it...
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
Avid Bioservices' (CDMO) CEO Nick Green on Q3 2022 Results - Earnings Call Transcript
Avid Bioservices' (CDMO) CEO Nick Green on Q3 2022 Results - Earnings Call Transcript
Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know
Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.
Avid Bioservices Expands Production Capacity To Continue Growth Trajectory
One unduly sold-off company of late is Avid Bioservices, with only positive news of late guiding to performance beyond expectations.
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?
Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon.
Avid Bioservices (CDMO) Loses 24.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Avid Bioservices (CDMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
Source: https://incomestatements.info
Category: Stock Reports